CooperCompanies (NASDAQ: COO), a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.
For the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up from $0.85 in the prior-year period.
Encouraged by the strong start to the fiscal year, the company raised its full-year 2025 non-GAAP EPS guidance to a range of $3.94 to $4.02, up from its previous outlook of $3.92 to $4.02. Management commented on their confidence in delivering robust growth and operational excellence going forward.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。